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Streptococcal hypersensitivity reloaded: severe
inflammatory syndrome in Behc¸et’s disease
following 23-valent polysaccharide Streptococcus
pneumoniae vaccine
SIR, Infections with Streptococcus pneumoniae are a
significant cause of morbidity and mortality in patients
with autoimmune inflammatory rheumatic diseases. The
European League Against Rheumatism (EULAR) recom-
mends the 23-valent polysaccharide pneumococcal
vaccine (23-PPV) in patients with inflammatory rheumatic
diseases, including Behc¸et’s disease (BD) [1]. Pneu-
mococcal vaccine safety was tested in RA, juvenile arth-
ritis and SLE [2] and no significant local or systemic
adverse events and disease flares were reported.
We have recently implemented the EULAR recommen-
dations in our outpatient service by systematically vacci-
nating patients with autoimmune inflammatory rheumatic
diseases if they are treated with immunosuppressive
agents. Subsequently we have observed four patients
with BD who developed severe local reactions to the
first application of 23-PPV at the injection site as well as
a severe systemic inflammatory response. No systemic
adverse reactions were observed in patients of our service
who received 23-PPV for autoimmune conditions other
than BD.
The clinical features of the four patients are summarized
in Table 1. The three male patients fulfilled the criteria for
BD and the female patient had an incomplete phenotype
of BD with oral ulcers, oligoarthritis and HLA-B51 geno-
type positivity. The mean disease duration of BD was
9.5 years. All of the patients had been vaccinated against
influenza and tetanus without complication, one also had
received hepatitis A and tick-borne encephalitis vaccines
without adverse reactions. The local adverse reaction to
the 23-PPV originating from different charges was similar
in all of the patients and developed 48 h after the injec-
tion, with pain, redness and local swelling (spreading
15 cm from the injection site); urticarial lesions were
not observed. Whereas the local symptoms resolved com-
pletely after 1 day in the female patient, the three males
developed a severe systemic inflammation with malaise,
high fever, chills and vomiting. Leucocyte counts in-
creased to a maximum of 20.5 109/l and the CRP to
385 mg/l. All symptoms resolved in a few days with local
cooling, paracetamol, anti-inflammatory non-steroidal
drugs and i.v. fluids. In one patient, the initially diffuse
swelling at the injection site, which extended from the
acromion to the elbow, turned into a profound pseudofol-
liculitis, prior to complete resolution (supplementary
figure).
There are several possible explanations for this severe
adverse reaction. Pneumovax 23 is the currently licensed
pneumococcal polysaccharide vaccine. A 0.5 ml dose of
this vaccine contains 25 mg of polysaccharides from the
23 most prevalent or invasive pneumococcal types in iso-
tonic saline, plus 0.25% phenol as preservative. Minor
local injection reactions are frequently observed, whereas
the incidence of severe vaccine-related systemic adverse
events is low. Phenol is used in many vaccines as a pre-
servative with low immunogenic properties. It is therefore
unlikely that phenol contributed to the adverse reactions.
BD is considered an autoinflammatory multisystem dis-
ease. An overreacting immune system with neutrophil
hyperfunction, also described as pathergy, is frequently
encountered. For pathergy testing, a sterile needle is
used to obliquely penetrate the skin, provoking a local
induration after 48 h. Pathergy-like inflammatory reactions
can also be triggered by insults such as trauma, athro-
centesis or surgery, and then affect organs other than
the skin [3]. However, three of the reported patients here
had negative pathergy testing.
In patients with BD, elevated antibody titres directed
against streptococci in the oral flora have been detected
and skin hypersensitivity against streptococci has been
included in the Japanese diagnostic criteria for BD [4].
An immune reaction to one or several of the 23 polysac-
charides by pre-existing anti-streptococcal antibodies or
an IgE-mediated anaphylactic reaction could therefore ex-
plain some symptoms of the patients, although the time
course and the clinical features make the latter pathome-
chanism unlikely. The systemic inflammatory reactions in
our cohort contrast to reports of local BD symptoms that
occurred after streptococcal antigen exposure [5]. This
divergence may be accounted by the obvious difference
in the streptococcus species, as well as by different
amounts of antigen and route of exposure. Interestingly,
the mildest reaction was observed in the patient with in-
complete BD who only received ibuprofen. To what extent
etanercept, abatacept or AZA further influenced the
symptoms in the other three patients remains speculative
at this point.
More recently, BD has been proposed as an autoinflam-
matory disease secondary to an aberrant activation of the
inflammasome, a complex modular structure that acti-
vates IL-1b [6]. In this context, it is interesting to note
that 23-PPV can activate toll-like receptors (TLRs) 2 and
4 as known triggers of sterile inflammation [7]. TLR trig-
gering by 23-PPV components with subsequent inflam-
masome activation via IL-1b in a predisposed host could
explain the rapid onset of the adverse reaction, the occur-
rence of high fever and the neutrophilic nature of the sys-
temic inflammatory response. Our observations may also
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have implications for other autoinflammatory diseases [6].
We suggest that the safety of pneumococcal vaccination
with 23-PPV in BD patients should be further investigated.
Rheumatology key message
. Pneumococcal vaccine can trigger severe inflam-
mation in BD, possibly by inflammasome activation.
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EF/SSc overlap syndrome and aplastic anaemia
resistant to immunosuppressive therapy
SIR, EF (Shulman syndrome) is a rare fibrosing disorder,
usually associated with a good prognosis, with spontan-
eous remission or remission after CS therapy. However, it
is frequently associated with haematological disorders; to
our knowledge, 25 cases of aplastic anaemia (AA) or pan-
cytopenia in the setting of EF have been reported [1]. In
these cases, although the semiological description of der-
matological abnormalities was often poor, clinical signs of
SSc were often absent. EF and SSc are generally con-
sidered to be two distinct diseases.
TABLE 1 Clinical characteristics of four patients with features of BD who developed severe inflammation after receiving
23-valent pneumococcal vaccination
Age,
years/
gender Origin
Clinical
presentation
of BD
Disease
duration,
years
HLA
allele
Pathergy
testing
BD treatment
at vaccination
Symptoms
after
vaccination
32/male Swiss Recurrent aphthous oral
ulcers, genital ulcers,
pseudofolliculitis,
erythema nodosum,
arthralgia,
thrombophlebitis,
cerebral venous
thrombosis,
retinochoroiditis
11 B51+ ND Abatacept,
prednisolone
(20 mg)
Day 1: ipsilateral axillar pain,
redness, calor and
tenderness at the injection
site Day 2: fever (40.0C),
chills, nausea and vomiting,
CRP 385 mg/l Day 3:
pseudofolliculitis at injection
site (supplementary figure)
41/male Turkish Recurrent aphthous oral
ulcers, genital ulcers,
arthritis, erythema
nodosum,
pseudofolliculitis
6 ND Negative Etanercept Day 1: local pain, calor,
redness and swelling, fever
(38.9C), CRP 223 mg/l,
headache, shivering,
dyspnoea
41/female Turkish Recurrent aphthous oral
ulcers, oligoarthritis
6 B51+ Negative Ibuprofen Day 1: local pain, calor and
swelling at injection site
after 1 h
46/male Turkish Recurrent aphthous oral
ulcers, pseudofolliculitis,
thrombophlebitis, uveitis
15 B51+ Negative AZA Day 1: local pain, calor,
swelling, fever (40C),
asthenia, CRP 158 mg/l
ND: no data.
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